Member Info for Newuncle

It never ceases to amaze me how many so called "experts" feel the need to trash talk others shares, it's pathetic behaviour from social media types who know FA in reality.

The partnership with Schurter will deliver huge opportunities for CPX.

Add the new American market being being developed.

And lots more to come.

Buys being shown as sells now due to spread

Do stfu lisa with your fud

Pretty bullish update

I'm not seeing enough buying but seller(s) still going at it......

This will relist on......any day coming ending with a y...excluding weekends, xmas day and boxing day

Retail price of £905....guess most will claim through their insurance if possible. Wonder what price from OBD is set at?

And the seller is having to sell bigger volumes more often now. It will be a buy again at some point of course but is it a case of waiting for decent news or not?

So Affrm,

You have zero concerns on anything here then?

Just asking fwiw

Looks like everyone is sitting on their hands now and waiting for the seller to clear.

Sub £4m Mcap but little sign the seller is done here and no one wants to catch that falling knife yet.

Ok, lets just keep it simple, current MCAP is £17m, is that cheap, fair value or over priced and why?

Stuart is 100% correct there

Rob,

Me too and others as well. If you are not part of the happy clappy millionaires gang of groupies there it offers nothing.

Now I can see that's being played out here too.

Not allowed to question anything or anyone's assumptions of the enormous riches to come here.

Just have to wait for the bank of PPP cashpoint to open and start spewing out £50 notes for everyone.

No it isn't becoming tedious

It is tedious, very, very tedious...LSE board is being turned into a carbon copy of the telegram group

Nothing ventured, Nothing gained as they say, at least you know the risks and can quantify them to some extent v the opportunity.

For me, the upside is going to take a little longer than current MCAP supports.

A question and question mark related to OBD's ability to justify their £18 MCAP was what I meant.

I guess the next update after 30 Sept will address that for everyone.

I have concerns that progress will have been to slow on the revenues front and costs will have continued to rise to support current company valuation..

Not asking you anything, just pointing out that an £18m MCAP looks high without some revenue growth which I am not really seeing. In the last report the FD highlighted the following:

At the date of this report, a number of factors make it difficult to predict anticipated product and other commercial revenue and associated cash receipts, or income from any partnership or outlicensing agreement that may provide additional funds. Accordingly, as explained in more detail in Note 2 to the interim financial statements, the Board has concluded (as it did in the annual reports for the years ended 30 September 2022 and 30 September 2023) that there continues to be a material uncertainty which may cast significant doubt on the Group's ability to continue as a going concern.

We plan to update shareholders on progress towards the Group's aims over the remainder of the year, including provision of order volumes for PSE and CiRT for the financial year, shortly after 30 September 2024.

From Shore Cap Note in June

For the future, the sheer size and opportunity of the PSE test once successfully commercialised is the key to supporting future financial independence of the company and the company achieves its 1000 tests per month objective. Inevitably, the increased activity generally with increased lab space and additional (more experienced) sales hires as OBD seeks to optimise its commercial business model has led to increased costs and an operating loss of £6.0m. We note that the company bolstered its cash resources by raising £9.9m gross in March 2024 and we look forward to the potential for the company to secure partners for the canine cancer (EpiSwitch SCB) and colorectal cancer (EpiSwitch NST) programmes which could boost cash resources.

With an MCAP of £18m, OBD has a lot to prove why/how that is valid?